InvestorsHub Logo
Followers 53
Posts 1783
Boards Moderated 0
Alias Born 03/22/2015

Re: no2koolaid post# 290743

Tuesday, 06/05/2018 11:14:26 PM

Tuesday, June 05, 2018 11:14:26 PM

Post# of 403106

Let me clear up the confusion






Great job this week, N2K. Multiple strong posts both days, fighting the good fight. I know what it means when I see significant increases in the frequency and audacity of misinformation. It means there is no ammunition based in truth. It means there is desperation triggered by the company's progress. Two awesome PR's back-to-back last week caused a frowny frenzy this week. Great job clearing up the confusion.



..with the option to add products in the future.





The SunGen and Glenmark PR's complement each other perfectly. Glenmark will allow Elite's drugs to gain more market share sooner, including future SunGen drugs, and maybe older Mikah drugs coming back from Epic. I especially like that neither of last week's PR's were about ADF opioids. Lately it feels like having the best ADF tech is like having the prize-winning rhubarb pie at the county fair. You get a blue ribbon same as the others, but apple and cherry get the real glory. I still believe that requiring IR opioids to have a quality ADF, like ELTP's 2 bead antagonist tech, is one of the few things we could do as a nation to help staunch the epidemic of opioid addiction in young people, but I do not see any evidence it will happen soon. SequestOx is an important drug that will fill an unmet need of critical importance, but with fluctuating trends in opioid prescribing and uncertain penetration of ADF’s, it is important to insulate the company by diversifying the pipeline. Whatever happens with opioids and ADF's, SunGen and Glenmark guarantee our factory will be busy. With these agreements, Nasrat is effectively setting the table and shaping the future of the company.







Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News